Anterior uveitis is an eye inflammation that involves middle layer of the eye specifically, iris (colored part of the eye) and ciliary body (adjacent tissue). Untreated anterior uveitis results in loss of vision and permanent eye damage that arises with the development of infections such as glaucoma, retinal edema or cataract. Anterior uveitis can be treated with eye drops containing anti-inflammatory drugs. It usually responds well to treatment. However, there may be a tendency of the condition to re-occur. Uveitis remains a less-explored research indication that involves diverse therapeutics as treatment options including corticosteroids and biologics. Corticosteroids showed significant results to cure the condition and researchers are currently exploring biological therapies to treat anterior uveitis. Introduction of biologics such as Humira (Adalimumab) for the treatment uveitis is driving the growth of anterior uveitis market in Asia pacific. Exploring new drugs and expanding therapeutic applications of existing drugs to include and effectively treat uveitis offers significant growth opportunity for companies involved in uveitis market.
★
★
★
★
★
296 views • 7 slides
